PLRX
PLRX clinical trials: PLIANT THERAPEUTICS, INC.
Every trial on ClinicalTrials.gov where PLIANT THERAPEUTICS, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 7
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
PLRX on the catalyst calendar · PLRX registry changes
- Primary completion Jun 2030Sponsor estimatePhase 1NCT06270706A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPliant Therapeutics, Inc. · Advanced or Metastatic Solid TumorRecruitingPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 4, 2025ActualPhase 2NCT06097260Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisPliant Therapeutics, Inc. · Idiopathic Pulmonary FibrosisTerminatedPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 26, 2024ActualPhase 2NCT04480840Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC)Pliant Therapeutics, Inc. · Primary Sclerosing CholangitisCompletedPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 27, 2023ActualPhase 2NCT05621252Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)Pliant Therapeutics, Inc. · Idiopathic Pulmonary FibrosisCompletedPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2023ActualPhase 2NCT04396756Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary FibrosisPliant Therapeutics, Inc. · Idiopathic Pulmonary FibrosisCompletedPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2022ActualPhase 2NCT04072315Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/Pliant Therapeutics, Inc. · Idiopathic Pulmonary FibrosisCompletedPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 1, 2021ActualPhase 2NCT04565249Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome...Pliant Therapeutics, Inc. · Acute Respiratory Distress SyndromeTerminatedPLRXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 25, 2023ActualEarly Phase 1NCT03183570Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CTStanford University · Idiopathic Pulmonary FibrosisCompletedPLRXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner